Skip to content
10-Q

Quarterly Report

IOVANCE BIOTHERAPEUTICS, INC. IOVA

0001104659-25-107470

← back to feed
Filed
Nov 6, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Oct 15, 2025 396.97M sh
Capex Q3 2025 · Sep 30, 2025 $24.52M
Capex Q3 2025 · Sep 30, 2024 $6.9M
Operating Cash Flow Q3 2025 · Sep 30, 2025 −$249.84M
Operating Cash Flow Q3 2025 · Sep 30, 2024 −$279.68M
Short Term Investments Q3 2025 · Sep 30, 2025 $142.67M
Short Term Investments Q3 2025 · Dec 31, 2024 $208.09M
Cash And Equivalents Q3 2025 · Sep 30, 2025 $158.13M
Cash And Equivalents Q3 2025 · Dec 31, 2024 $115.69M
Cash And Equivalents Q3 2025 · Sep 30, 2024 $164.19M
Stockholders Equity Q3 2025 · Sep 30, 2025 $702.29M
Stockholders Equity Q3 2025 · Jun 30, 2025 $698.49M
Stockholders Equity Q3 2025 · Dec 31, 2024 $710.41M
Stockholders Equity Q3 2025 · Sep 30, 2024 $773.46M
Stockholders Equity Q3 2025 · Jun 30, 2024 $768.54M
Stockholders Equity Q3 2025 · Dec 31, 2023 $584.61M
Current Liabilities Q3 2025 · Sep 30, 2025 $125.79M
Current Liabilities Q3 2025 · Dec 31, 2024 $122.34M
Total Liabilities Q3 2025 · Sep 30, 2025 $202.66M
Total Liabilities Q3 2025 · Dec 31, 2024 $200.02M
Current Assets Q3 2025 · Sep 30, 2025 $429.09M
Current Assets Q3 2025 · Dec 31, 2024 $457.02M
Total Assets Q3 2025 · Sep 30, 2025 $904.95M
Total Assets Q3 2025 · Dec 31, 2024 $910.43M
Eps Basic Q3 2025 · Sep 30, 2025 −$0.25
Eps Basic Q3 2025 · Sep 30, 2025 −$0.94
Eps Basic Q3 2025 · Sep 30, 2024 −$0.28
Eps Basic Q3 2025 · Sep 30, 2024 −$1.03
Sga Expense Q3 2025 · Sep 30, 2025 $34.56M
Sga Expense Q3 2025 · Sep 30, 2025 $115.92M
Sga Expense restated Q3 2025 · Sep 30, 2024 $39.34M
Sga Expense restated Q3 2025 · Sep 30, 2024 $109.95M
Rd Expense Q3 2025 · Sep 30, 2025 $75.17M
Rd Expense Q3 2025 · Sep 30, 2025 $229.07M
Rd Expense restated Q3 2025 · Sep 30, 2024 $67.04M
Rd Expense restated Q3 2025 · Sep 30, 2024 $205.22M
Net Income Q3 2025 · Sep 30, 2025 −$91.25M
Net Income Q3 2025 · Sep 30, 2025 −$319.07M
Net Income Q3 2025 · Sep 30, 2024 −$83.54M
Net Income Q3 2025 · Sep 30, 2024 −$293.62M
Operating Income Q3 2025 · Sep 30, 2025 −$94.9M
Operating Income Q3 2025 · Sep 30, 2025 −$329.9M
Operating Income Q3 2025 · Sep 30, 2024 −$89.07M
Operating Income Q3 2025 · Sep 30, 2024 −$308.7M
Cost Of Revenue Q3 2025 · Sep 30, 2025 $38.48M
Cost Of Revenue Q3 2025 · Sep 30, 2025 $130.07M
Cost Of Revenue restated Q3 2025 · Sep 30, 2024 $31.52M
Cost Of Revenue restated Q3 2025 · Sep 30, 2024 $55.46M
Revenue Q3 2025 · Sep 30, 2025 $67.46M
Revenue Q3 2025 · Sep 30, 2025 $176.73M
Revenue Q3 2025 · Sep 30, 2024 $58.56M
Revenue Q3 2025 · Sep 30, 2024 $90.38M